Clin2
NCT06468098Likely a fitRecruiting

Study of IBI363 for advanced cancer

Advanced Malignancies

Treatments studied

Part of Cancer clinical trials.

This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
556 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have advanced cancer that has been confirmed by a biopsy or other lab test.
  • Your cancer has gotten worse after standard treatment, or you cannot have standard treatment, or you have chosen not to have it.
  • You have at least one tumor that can be measured on a scan.
  • You are able to take care of yourself (ECOG score 0 or 1).
  • You agree to use effective birth control during the study and for 6 months after the last dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06717880Recruiting· Phase 1
Combination therapy for advanced colorectal cancer

This trial tests a new drug (IBI363) combined with either bevacizumab or furuitinib for people with advanced colorectal cancer that has worsened after standard treatments. It aims to find a more effective option for those who have limited alternatives.

Wuhan, Hubei
NCT06610799Recruiting· Phase 1
Study of IBI363 for first-line advanced gastric cancer

This trial tests a new drug called IBI363 in patients with advanced gastric or gastroesophageal junction cancer who have not yet received any treatment. The goal is to see if the drug can help shrink tumors or slow the cancer's growth.

Hangzhou, Zhejiang
NCT07325630Recruiting· Phase 2
Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer

This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.

Hangzhou, Zhejiang
NCT07483554Recruiting· Phase 2
IBI343 combination therapy for advanced solid tumors

This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.

Hangzhou, Zhejiang
NCT06281678Recruiting· Phase 2
Study of IBI363 for advanced solid tumors

This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.

San Francisco, California
NCT06081907Recruiting· Phase 1/Phase 2
IBI363 for advanced solid tumors

This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.

Changsha, Hunan

Hear when a new Advanced Malignancies trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.